Archives

  • 2026-10
  • 2026-09
  • 2026-08
  • 2026-07
  • 2026-06
  • 2026-05
  • 2026-04
  • 2026-03
  • 2026-02
  • 2026-01
  • 2025-12
  • 2025-11
  • 2025-10
  • 2025-09
  • 2025-03
  • 2025-02
  • 2025-01
  • 2024-12
  • 2024-11
  • 2024-10
  • 2024-09
  • 2024-08
  • 2024-07
  • 2024-06
  • 2024-05
  • 2024-04
  • 2024-03
  • 2024-02
  • 2024-01
  • 2023-12
  • 2023-11
  • 2023-10
  • 2023-09
  • 2023-08
  • 2023-07
  • 2023-06
  • 2023-05
  • 2023-04
  • 2023-03
  • 2023-02
  • 2023-01
  • 2022-12
  • 2022-11
  • 2022-10
  • 2022-09
  • 2022-08
  • 2022-07
  • 2022-06
  • 2022-05
  • 2022-04
  • 2022-03
  • 2022-02
  • 2022-01

    • Clozapine N-oxide (CNO): Chemogenetic Actuator for Neuros...

    2026-01-28

    Clozapine N-oxide (CNO): Chemogenetic Actuator for Neuroscience

    Executive Summary: Clozapine N-oxide (CNO), supplied by APExBIO (A3317), is a major metabolite of clozapine and a highly selective chemogenetic actuator that enables non-invasive, reversible modulation of neuronal activity via engineered muscarinic DREADDs receptors (APExBIO). CNO is biologically inert in typical mammalian systems, minimizing off-target effects in native tissues (Chen et al., 2025). It reduces 5-HT2 receptor density and inhibits phosphoinositide hydrolysis in specific neuronal models. CNO is highly soluble in DMSO but insoluble in water and ethanol, requiring warming or ultrasonic shaking for optimal dissolution. Its specificity and validated use in chemogenetic studies position CNO as a critical tool for GPCR signaling and translational neuroscience research.

    Biological Rationale

    Clozapine N-oxide (CNO; CAS 34233-69-7) is a principal metabolic derivative of clozapine, an atypical antipsychotic. Unlike its parent compound, CNO exhibits negligible affinity for endogenous mammalian neurotransmitter receptors at relevant concentrations (APExBIO). This biological inertness is crucial for chemogenetic applications, as it limits unwanted receptor interactions and ensures that observed effects are due to the activation of engineered receptors. CNO is primarily employed to activate designer receptors exclusively activated by designer drugs (DREADDs), which are mutated muscarinic receptors introduced via viral vectors or transgenic techniques. This allows neuroscientists to precisely control neuronal activity both in vitro and in vivo, supporting causal studies in complex neuropsychiatric and behavioral contexts (see related: CNO in translational research; this article focuses more on selectivity and workflow optimization).

    Mechanism of Action of Clozapine N-oxide (CNO)

    CNO acts as a selective agonist for engineered muscarinic receptors, particularly hM3Dq (Gq-coupled) and hM4Di (Gi/o-coupled) DREADDs. Upon systemic administration, CNO crosses the blood–brain barrier and binds DREADDs, inducing downstream G protein-coupled receptor (GPCR) signaling. This modulates neuronal excitability; for example, hM3Dq activation depolarizes neurons, while hM4Di activation hyperpolarizes them (Chen et al., 2025). CNO does not significantly interact with native muscarinic, dopaminergic, or serotonergic receptors at typical experimental concentrations. In cultured rat cortical neurons, CNO reduces 5-HT2 receptor density and inhibits phosphoinositide hydrolysis stimulated by serotonin (5-HT), with these effects being concentration-dependent (typically 1–100 μM in vitro) (APExBIO).

    Evidence & Benchmarks

    • CNO enables reversible, temporally precise modulation of neuronal circuits in vivo using DREADDs, as validated in mouse models of depression and Parkinson’s disease (Chen et al., 2025, DOI).
    • Systemic CNO administration at 1–10 mg/kg induces behavioral changes only in animals expressing DREADDs, confirming its selectivity (APExBIO).
    • CNO is highly soluble (>10 mM) in DMSO at 25–37°C, but insoluble in water and ethanol; ultrasonic shaking or warming at 37°C enhances dissolution (APExBIO).
    • Long-term storage of CNO solutions at -20°C preserves chemical stability for several months, but repeated freeze–thaw cycles are discouraged (APExBIO product data sheet, link).
    • Clinical studies confirm that CNO is metabolized reversibly to clozapine in humans, with pharmacokinetic monitoring required in translational studies (APExBIO).
    • Activation of DREADDs by CNO in the ventral tegmental area (VTA)–nucleus accumbens (NAc) pathway modulates depressive-like behaviors in mice, demonstrating utility for circuit-level interrogation (Chen et al., 2025).

    Applications, Limits & Misconceptions

    CNO is a core tool for chemogenetic interrogation of neuronal circuits. It is widely used for:

    • Mapping the functional connectivity of defined neuronal populations via DREADDs activation.
    • Studying GPCR-driven signaling cascades relevant to neuropsychiatric disorders, including depression and schizophrenia.
    • Translational research bridging rodent, non-human primate, and human systems, particularly in behavioral paradigms.

    This article extends the coverage of CNO’s role in circuit-mapping and schizophrenia research by detailing workflow integration and storage/solubility optimization, as well as summarizing updated clinical findings.

    Common Pitfalls or Misconceptions

    • Off-target effects in vivo: At standard doses, CNO is considered inert in wild-type rodents, but back-conversion to clozapine can occur in some species, leading to mild off-target effects—particularly in humans and non-human primates (Chen et al., 2025).
    • Solubility errors: Attempting to dissolve CNO in water or ethanol yields precipitates; always use DMSO and optimize with warming or sonication (APExBIO).
    • Storage mistakes: Prepared stock solutions should not be stored long-term; use fresh aliquots and avoid repeated freeze–thaw cycles to maintain activity (APExBIO).
    • Species-specific metabolism: In some mammals, especially humans, CNO can be partially metabolized back to clozapine, necessitating pharmacokinetic controls in translational research (see related discussion).
    • Assuming universal efficacy: CNO only modulates cells expressing DREADDs; native neuronal populations lacking these receptors are unaffected at standard concentrations.

    Workflow Integration & Parameters

    CNO is supplied as a dry powder that should be stored at -20°C. For experimental use, dissolve CNO in DMSO at concentrations >10 mM, using a water bath at 37°C or ultrasonic agitation to facilitate solubilization. Prepare aliquots to minimize freeze–thaw cycles. Stock solutions should be stored at -20°C and used within several months; avoid long-term storage of working solutions. For in vivo studies, typical systemic doses range from 1–10 mg/kg, administered intraperitoneally. For in vitro applications, concentrations of 1–100 μM are common. Always include vehicle controls due to occasional species-specific metabolism. For further insight into experimental design and troubleshooting, see CNO’s role in advanced chemogenetic strategies; this article adds detailed solubility and storage guidance.

    Conclusion & Outlook

    Clozapine N-oxide (CNO) is a validated, selective chemogenetic actuator that enables precise, reversible control of neuronal circuits through DREADDs technology. Its inertness in native mammalian systems, combined with robust solubility and storage protocols, make it an essential tool for neuroscience research and translational applications. APExBIO’s A3317 CNO product is supported by extensive peer-reviewed evidence and optimized for both in vitro and in vivo workflows. Future developments include more refined DREADDs variants and next-generation chemogenetic actuators for circuit-specific interventions in neuropsychiatric disease models.